Chr. Hansen has reported a strong second quarter for fiscal year 2013/14, highlighted by revenues of EUR182 million (US$253) and 10 percent organic growth. The animal health and nutrition company also reported revenues unchanged from the first half of the previous fiscal year at EUR353 million (US$490 million)
Chr. Hansen CEO Cees de Jong expects the continued financial success for the remainder of the fiscal year.
"Following a strong Q2 with 10 percent organic growth and solid margin development, we remain on track to deliver on our outlook for the full year, expecting organic revenue growth of 7 to 9 percent and an EBIT margin before special items above 26 percent," said de Jong.
"We have continued to implement our Nature's No. 1 strategy with initiatives to support the future growth and profitability of Chr. Hansen. I am especially pleased with the good performance of both the Cultures & Enzymes Division and the EMEA region in general as well as to see the first sales of cultures for crop protection."